Previous 10 | Next 10 |
Topline results from a Phase 1 clinical trial evaluating Ionis Pharmaceuticals (NASDAQ: IONS ) affiliate Akcea Therapeutics' (NASDAQ: AKCA ) AKCEA-TTR-Lrx in healthy volunteers showed a treatment effect. The data were presented at the Heart Failure Society of American Annual Scientific Me...
Data show >90% knockdown of TTR following administration in healthy volunteers Positive safety and tolerability profile for LICA platform-based therapy Phase 3 program on track to start later this year in patients with all forms of TTR amyloidosis BOSTON and CARLSBAD, Calif....
Multiple presentations on the long-term efficacy and safety of TEGSEDI ® (inotersen) in patients with polyneuropathy caused by hATTR Amyloidosis Topline data results to be presented from the Phase 1 study of AKCEA-TTR-L Rx for the treatment of Transthyretin Amyloidosi...
Market Assessment Akcea Therapeutics ( AKCA ), a subsidiary of Ionis Pharmaceuticals ( IONS ), is a commercial-stage small-cap ($1.98B) that was founded in 2014. Akcea's scientific forte is developing innovative therapeutics to treat rare and life-ending hereditary diseases associated with...
In terms of controlling what they can control, I believe Alnylam Pharmaceuticals ( ALNY ) management is doing a good job. While there has certainly been criticism of the high cash burn and the large sums that the company spends on R&D, I believe funding a robust Phase III development pro...
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you c...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Podcast listener? Subscribe now to receive Wall Street Breakfast by 8:00 a.m. every t...
Regeneron Pharmaceuticals (NASDAQ: REGN ) announces the successful outcome of a Phase 3 clinical trial, ELIPSE HoFH , evaluating evinacumab in patients with an inherited form of severely elevated levels of "bad" (LDL-C) cholesterol called homozygous familial hypercholesterolemia (HoFH). ...
Mean triglyceride levels decreased 77% in volanesorsen-treated patients versus an 18% increase in patients in placebo group Akcea launching WAYLIVRA in the European Union BOSTON and CARLSBAD, Calif, Aug. 07, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affili...
Akcea Therapeutics, Inc. (AKCA) Q2 2019 Earnings Conference Call Aug 6, 2019 4:30 PM ET Company Participants Kathleen Gallagher - Vice President of Corporate Communications & Investor Relations Paula Soteropoulos - Chief Executive Officer Sarah Boyce - President Jeff Goldeb...
News, Short Squeeze, Breakout and More Instantly...
Akcea Therapeutics Inc. Company Name:
AKCA Stock Symbol:
NASDAQ Market:
Akcea Therapeutics Inc. Website:
Ionis and Akcea win prestigious Prix Galien Award for TEGSEDI® (inotersen) as Best Biotechnology Product PR Newswire BOSTON and CARLSBAD, Calif., Oct. 30, 2020 BOSTON and CARLSBAD, Calif. , Oct. 30, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, In...
Ionis Pharmaceuticals completes acquisition of Akcea Therapeutics Transaction creates a stronger, more efficient company PR Newswire CARLSBAD, Calif., Oct. 12, 2020 CARLSBAD, Calif. , Oct. 12, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS...
NEW YORK, NY / ACCESSWIRE / September 23, 2020 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City, is investigating: Akcea Therapeutics, Inc. (NASDAQ: AKCA ), relating...